{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T14:47:50Z","timestamp":1775227670888,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T00:00:00Z","timestamp":1527638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.jmii.2018.05.003","type":"journal-article","created":{"date-parts":[[2018,6,2]],"date-time":"2018-06-02T12:09:56Z","timestamp":1527941396000},"page":"158-162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse\u00a0events"],"prefix":"10.1016","volume":"52","author":[{"given":"Shang-Yi","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Wen","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7423-6783","authenticated-orcid":false,"given":"Po-Liang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shang-Jyh","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9258-0692","authenticated-orcid":false,"given":"Tun-Chieh","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Han","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8667-4844","authenticated-orcid":false,"given":"Yen-Hsu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmii.2018.05.003_bib1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1471-2369-10-36","article-title":"Risk factors for tuberculosis in dialysis patients: a prospective multi-center clinical trial","volume":"10","author":"Christopoulos","year":"2009","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.jmii.2018.05.003_bib2","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1183\/13993003.01245-2015","article-title":"Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries","volume":"46","author":"Getahun","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jmii.2018.05.003_bib3","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/cid\/cix505","article-title":"High rate of treatment completion in program settings with 12-dose weekly isoniazid and rifapentine (3HP) for latent Mycobacterium tuberculosis infection","volume":"65","author":"Sandul","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2018.05.003_bib4","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2018.05.003_bib5","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/cid\/civ323","article-title":"Flu-like and other systemic drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the PREVENT tuberculosis study","volume":"61","author":"Sterling","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2018.05.003_bib6","doi-asserted-by":"crossref","first-page":"e4126","DOI":"10.1097\/MD.0000000000004126","article-title":"Impacts of 12-dose regimen for latent tuberculosis infection: treatment completion rate and cost-effectiveness in Taiwan","volume":"95","author":"Huang","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jmii.2018.05.003_bib7","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/MAJ.0b013e31814a586a","article-title":"Update on rifampin and rifabutin drug interactions","volume":"335","author":"Baciewicz","year":"2008","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jmii.2018.05.003_bib8","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1399-3062.2005.00103.x","article-title":"Prospective randomized control trial of isoniazid chemoprophylaxis during renal replacement therapy","volume":"7","author":"Vikrant","year":"2005","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jmii.2018.05.003_bib9","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1159\/000187331","article-title":"Isoniazid-induced neurotoxicity in chronic dialysis patients: report of three cases and a review of the literature","volume":"64","author":"Siskind","year":"1993","journal-title":"Nephron"},{"key":"10.1016\/j.jmii.2018.05.003_bib10","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/tri.12881","article-title":"Severe hypertension after initiation of rifapentine\/isoniazid for latent tuberculosis in renal transplant candidates","volume":"30","author":"Simkins","year":"2017","journal-title":"Transpl Int"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118218301531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118218301531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:24:36Z","timestamp":1761657876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1684118218301531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S1684118218301531"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2018.05.003","relation":{},"ISSN":["1684-1182"],"issn-type":[{"value":"1684-1182","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse\u00a0events","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2018.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}